The fibroblast-driven melanoma/Treg vitiligo mouse model is effectively suppressed by IFNγ blocking antibody.

The use of immunosuppressive drugs for vitiligo treatment carries a potential risk of increased infection, whereas IFNγ bispecific antibodies represent an alternative therapeutic strategy. Researchers employing the melanoma/Treg vitiligo mouse model identified a critical role of dermal fibroblasts during the progressive phase of vitiligo. These fibroblasts respond to IFNγ and recruit CD8 + T cells, a mechanism that also contributes to the bilateral symmetrical depigmentation commonly observed in vitiligo patients. To evaluate the suitability of this model as a platform for developing fibroblast-targeted IFNγ bispecific antibodies, mice were administered regular injections of IFNγ monoclonal antibodies. The IFNγ monoclonal antibody treatment significantly suppressed vitiligo progression in the melanoma/Treg model. Owing to its advantages-including straightforward induction, multi-antigen specificity, and the demonstrated efficacy of IFNγ blocking antibodies, the melanoma/Treg vitiligo mouse model is a robust platform for advancing the development of fibroblast-targeted IFNγ bispecific antibodies.